Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association

Safety monitoring is of paramount importance for vaccines authorized for emergent use (EUA) by the US Food and Drug Administration (FDA) against SARS-CoV-2. Mass immunization is an essential tool to end the current pandemic, but vaccine surveillance is necessary to identify any potentially associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogbebor, Osakpolor, Seth, Harshit, Min, Zaw, Bhanot, Nitin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086372/
https://www.ncbi.nlm.nih.gov/pubmed/33968610
http://dx.doi.org/10.1016/j.idcr.2021.e01143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086372/
https://www.ncbi.nlm.nih.gov/pubmed/33968610
http://dx.doi.org/10.1016/j.idcr.2021.e01143

Ejemplares similares